A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance
A Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of TLC-3595 in Subjects With Insulin Resistance
Sponsor: OrsoBio, Inc
Listed as NCT05665751, this PHASE2 trial focuses on Insulin Resistance and remains ongoing. Sponsored by OrsoBio, Inc, it has been updated 9 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Jan 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- OrsoBio, Inc
For direct contact, visit the study record on ClinicalTrials.gov .